Would you consider giving tamoxifen prophylaxis to young women with pathogenic BRCA2 muations who are <35 years old?

There is some evidence to support use of tamoxifen in non affected carriers. Secondary analyses of 288 patients who developed cancer in NSABP P-1 trial suggested a 62% risk reduction in incidence of breast cancers in known gBRCA 2 carriers,no benefit in gBRCA 1. This data is limited by fairly low nu...